Astellas and IBL to develop recombinant human protein made using transgenic silkworms

Published: 3-Jan-2014
Research & Development

Possibility of producing new medicines using this technology


Japanese pharmaceutical firm Astellas is to collaborate with Immuno-Biological Laboratories to develop pharmaceutical applications of recombinant human proteins made using transgenic silkworms.

The firms will examine and evaluate the production method and possibly develop new medicines.

IBL has developed a production system for the efficient secretion of soluble recombinant proteins in the cocoon of transgenic silkworms and has succeeded in the production of various useful proteins including antibodies and human collagen. The firm is actively progressing with the commercialisation of these proteins as raw materials for reagents in research, in vitro diagnostics, cosmetics and veterinary drugs.

  • Companies:
  • Astellas Pharma
See more

You may also like

Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Read more
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics

Trending Articles

  1. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  2. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  3. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  4. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  5. Macomics unveils Anti-Pan-LILRB monoclonal antibody programme Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Ingredients

Therapeutic: zolbetuximab for gastric cancer

Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Research & Development

Astellas invests $13m in cell and gene therapy innovation incubators

Japanese Astellas’ nearly $13m will make it a Founding Sponsor of LabCentral's new incubator with a core lab space for process development studies and a non-GMP pilot plant
Research & Development

Astellas and Anokion to collaborate on immune tolerance therapeutics

The creation of a new company, Kanyos, will enable the preclinical development of products for type 1 diabetes and coeliac disease
Research & Development

Astellas and Potenza link up to build a portfolio of immuno-oncology therapeutics

Astellas takes an option to buy Potenza at the end of the collaboration period
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Syntheses that cut costs and boost yields

Reworking drug syntheses using cheaper or more environmentally friendly ingredients and catalysts can increase margins dramatically. Dr Sarah Houlton reports on recent successes
Research & Development

Cancer Research UK to work with Astellas to find new cancer treatments

Initially focusing on drug targets to block the autophagy pathway in pancreatic cancer cells
Subscribe now